已发表论文

CAV2 通过 EGFR/PI3K/Akt 通路促进肾细胞癌的生长

 

Authors Liu F, Shangli Z, Hu Z

Received 2 May 2018

Accepted for publication 23 June 2018

Published 25 September 2018 Volume 2018:11 Pages 6209—6216

DOI https://doi.org/10.2147/OTT.S172803

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Manfred Beleut

Peer reviewer comments 2

Editor who approved publication: Dr Takuya Aoki

Background: Caveolin-2 (CAV2) is reported to have an important role in cancer. The following study investigated the expression and function of CAV2 in kidney cancer in vitro and in vivo.
Materials and methods: Real-time PCR, immunohistochemistry and Western blotting analysis were used to determine CAV2, epidermal growth factor receptor (EGFR), phosphatidylinositol 3-kinase (PI3K) and protein kinase B (Akt) in kidney cancer cell line OS-RC-2 and clinical specimens. The role of CAV2 in maintaining kidney cancer malignant phenotype was examined by wound healing assay, Matrigel invasion assays and mouse orthotopic xenograft model.
Results: Higher expression of CAV2 was found in renal cell carcinoma tissue compared to normal tissue. Furthermore, increased expression of CAV2 was associated with cancer progression. Also, silencing of CAV2 inhibited the proliferation, migration and invasion, as well as the expression of EGFR, PI3K and p-Akt in OS-RC-2 cells in vitro, and OS-RC-2 xenograft growth in vivo.
Conclusion: Our results revealed that CAV2 promotes the growth of renal cell carcinoma through EGFR/PI3K/Akt pathway.
Keywords: Caveolin-2, CAV2, EGFR, PI3K, p-Akt, renal cell carcinoma, invasion




Figure 2 CAV2 expression was detected by immunohistochemistry (IHC).